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Infanta b s t r a c t
Neonatal Bacille Calmette Guérin (BCG) vaccination has been reported to have beneﬁcial effects beyond
preventing infantile tuberculous meningitis and miliary disease. We hypothesized that BCG vaccine given
at birth would enhance T-helper 1 (Th1) immune responses to the ﬁrst vaccines given later in infancy. We
conducted a nested case-control study of neonatal BCG vaccination and its heterologous Th1 immune
effects in 2–3 months old infants. BCG vaccination at birth was associated with an increased frequency
of interferon-c (IFN-c) producing spot-forming cells (SFC) to tetanus toxoid 2–3 months later. The
frequency of IFN-c producing SFC to polioviruses 1–3 also trended higher among infants who received
BCG vaccination at birth. The frequency of IFN-c+/tumor necrosis factor-a (TNF-a)+CD45RO+CD4+ T-cells
upon stimulation with phorbol myristate acetate (PMA)/Ionomycin was higher in 2–3 months old infants
who received BCG vaccination at birth compared to those who did not. The circulating frequency of
forkhead box P3 (FoxP3)+ CD45RO+ regulatory CD4+ T-cells also trended lower in these infants. Neonatal
BCG vaccination is associated with heterologous Th1 immune effects 2–3 months later.
 2013 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The Bacille Calmette Guérin (BCG) vaccine is given to neonates
in most countries to prevent infantile tuberculous meningitis and
miliary disease. It is one of the most widely used vaccines world-
wide. The efﬁcacy of neonatal BCG administration has been linked
to its ability to effectively induce a T-helper 1 (Th1)-polarized neo-
natal immune response [1]. Th1 cells are effector andmemory CD4+
T-cells polarized to produce interferon-c (IFN-c). Neonates and in-
fants generally have reduced Th1 responses to many intracellular
pathogens and toxins [1]. Neonatal BCG vaccination has also been
reported to reduce neonatal and infant mortality due to diseases
other than tuberculosis [2–4]. Beneﬁcial heterologous immune ef-
fects on antibody responses to some routine infant immunizations
have been reported [5]. When given at age 2 months and at the
same time as other routine infant vaccines, BCG has been reportedto enhance the immune responses to some unrelated vaccines [6].
We hypothesized that BCG vaccine given at birth would enhance
Th1 immune responses to the ﬁrst vaccines given later in infancy.
In order to examine this hypothesis, we conducted a nested case-
control study of neonatal BCG vaccination. This study was within
an ongoing clinical study of dengue virus infections during infancy
in San Pablo, Laguna, Philippines. We found that BCG vaccination at
birth was associated with some heterologous Th1 immune effects
2–3 months later, particularly an increased frequency of IFN-c
producing spot-forming cells (SFC) to tetanus toxoid.Materials and methods
Ethics statement
The study protocol was approved by the institutional review
boards of the Research Institute for Tropical Medicine, Philippines,
and the University of Massachusetts Medical School. Mothers and
their healthy infants were recruited and enrolled after providing
written informed consent.
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The nested case-control study was drawn from an ongoing
clinical study of dengue virus infections during infancy that has
been previously described [7]. There were n = 13 infants who did
not receive BCG vaccine between birth and 2 weeks of age; they
received the BCG vaccine after their ﬁrst infant immunization with
the diphtheria/pertussis/tetanus toxoid vaccine (DPT) and oral
poliovirus vaccine (OPV) (cases). These infants did not receive
neonatal BCG because they were delivered at home in outlying
areas. There were n = 38 age- and sex-matched infants who
received BCG between birth and 2 weeks of age (controls). Vaccina-
tion dates were obtained from Expanded Programme in Immuniza-
tion (EPI) cards. Clinical and epidemiological information were also
collected at the study visit. Normalized child growth indicators
were determined using World Health Organization (WHO) child
growth standards. Peripheral blood mononuclear cells (PBMC)
were collected from infants at the ﬁrst study visit, at approxi-
mately 8–12 weeks old. PBMC were isolated using Histopaque
density centrifugation and cryopreserved.
IFN-c ELISPOT
Brieﬂy, cryopreserved PBMC (2–4  105 cells per well) were
thawed and seeded onto polyvinylidene diﬂuoride membrane
96-well plates (Millipore) precoated with 5 lg/ml anti-IFN-c
monoclonal antibody (clone D1K; Mabtech). Stimuli were tetanus
toxoid (EMD Calbiochem, 150 lg/ml), inactivated poliovirus
vaccine (Sanoﬁ Pasteur SA, 1/3.3 dilution), recombinant hepatitis
B surface antigen (Genway Biotech, 27 lg/ml), phytohemagglutinin
(PHA) (Sigma–Aldrich, 5 lg/ml), or media control (complete RPMI
1640/10% fetal calf serum). After 48 h of incubation (except PHA,
18–24 h incubation), cells were removed by washing with phos-
phate-buffered saline plus 0.05% Tween 20. Secondary biotinylated
anti-IFN-c monoclonal antibody (clone 7-B6-1; Mabtech) was
added at 2 lg/ml and the plates were incubated for 2 h at room
temperature. Plates were washed again and IFN-c was detected
with avidin–peroxidase (3420-2H, Mabtech) and substrate kit
(NovaRed, Vector Laboratories). The frequency of IFN-c-producing
cells was determined by using the ImmunoSpot S4 Pro Analyzer
and the ImmunoSpot Academic V.4 Software (Cellular Technologies
Ltd.). Experiments were performed in triplicate wells.
Flow cytometry
IFN-c and TNF-a secreting, and FoxP3+, CD4+ T-cells in infant
PBMC were identiﬁed by ICS (intracellular cytokine staining).
PBMC were washed with media, and then left unstimulated or
stimulated for 4 h with PMA/Ionomycin (BD Biosciences). The
stimulations were done in the presence of 1 ll Brefeldin A (BD
Biosciences). Cells were ﬁrst stained with surface Ab to CD45RO
(clone UCHL1), ﬁxed and permeabilized with the FoxP3 buffer set
(BD Biosciences), and then stained with Abs to CD3 (clone UCHT1),
CD4 (clone SK3), CD8 (clone SK1), IFN-c (clone B27), TNF-a (clone
6401.1111), and FoxP3 (clone 259D/C7) (all Abs from BD Biosci-
ences). Cells were analyzed using a FACSAria ﬂow cytometer (BD
Biosciences). LIVE/DEAD Fixable Dead Cell Stain Kit (LDA) (Invit-
rogen) was used to exclude nonviable cells from analysis. Relevant
cells were identiﬁed as LDA/CD3+/CD4+/CD8/CD45RO+ or
CD45RO/IFN-c+ or TNF-a+ or FoxP3+ cells (Supplementary
Fig. 1). Data was analyzed using FlowJo software (Treestar).
Statistical analysis
The SPSS software package (version 20.0) was used for statisti-
cal analyses. Comparisons between two continuous variables wereperformed using the non-parametric Mann–Whitney U test. Com-
parisons between categorical variables were performed using the
k2 test. P-values <0.05 were considered signiﬁcant. P-valuesP0.05
and <0.10 were considered a trend.Results
Case-control study of neonatal BCG vaccination
We conducted a nested case-control study of the heterologous
Th1 immune effects of neonatal BCG vaccination. The timing of
vaccinations, age at the time of PBMC collection, and characteris-
tics of infants in the case-control study are shown in Table 1. There
were no signiﬁcant differences in any measured variable between
infants in the case and control groups.Neonatal BCG vaccination is associated with an increased frequency of
IFN-c producing cells to tetanus toxoid and polioviruses in 2–3 months
old infants
We performed IFN-c ELISPOT assays to tetanus toxoid, poliovi-
ruses 1–3, hepatitis B surface antigen, and phytohemagglutinin
(PHA) in the PBMC from 2–3 months old infants. Neonatal BCG
vaccination was associated with an increased frequency of IFN-c
SFC to tetanus toxoid. The frequency of IFN-c SFC to polioviruses
1–3 (inactivated poliovirus vaccine) also trended higher among
infants who received BCG vaccination at birth (Fig. 1). There were
no differences in the frequencies of IFN-c SFC to hepatitis B surface
antigen or PHA between the infants who received neonatal BCG
vaccination and those who did not (Fig. 2). The frequencies of
IFN-c SFC to tetanus toxoid and polioviruses 1–3 were correlated
(Spearman r = 0.61, p < 0.001). The frequencies of IFN-c SFC to tet-
anus toxoid or polioviruses 1–3 did not correlate with IFN-c SFC to
either hepatitis B surface antigen or PHA.Neonatal BCG vaccination is associated with an increased frequency of
IFN-c+/TNF-a+ CD45RO+CD4+ T-cells upon PMA/Ionomycin
stimulation in PBMC from 2–3 months old infants
The gating strategies for ﬂow cytometry and intracellular cyto-
kine staining (ICS) are shown in Supplementary Fig. 1.We examined
IFN-c and TNF-a production in CD4+ T-cells upon PMA/Ionomycin
stimulation in the PBMC from 2–3 months old infants. BCG vaccina-
tionat birthwasassociatedwith an increased frequencyof PMA/Ion-
omycin-stimulated IFN-c+/TNF-a+ CD45RO+CD4+ T-cells during
early infancy. Therewasnodifference in the frequenciesof PMA/Ion-
omycin-stimulated IFN-c+/TNF-a+ CD45ROCD4+ T-cells between
infantswho received BCGvaccination at birth and thosewhodid not
(Fig. 3). Essentially all infant CD4+ T-cells that produced IFN-c upon
PMA/Ionomycin stimulation also produced TNF-a.Neonatal BCG vaccination is associated with a decreased trend of
circulating FoxP3+CD45RO+ regulatory CD4+ T-cells in 2–3 months
old infants
BCG vaccination at birth was associated with a decreased trend
in the circulating frequency of FoxP3+CD45RO+CD4+ T-cells
2–3 months later. FoxP3+CD4+ T-cells are considered to be mainly
regulatory T-cells (Tregs). There was no difference in the circulat-
ing frequencies of FoxP3+CD45RO CD4+ T-cells between infants
who received BCG vaccination at birth and those who did not
(Fig. 4). The vast majority of all CD4+ T-cells, including FoxP3+
CD4+ T-cells, in the infants were CD45RO (approximately 90%).
Table 1
Characteristics of the case-control study population.
Cases (neonatal BCG)a n = 13 Controls (+neonatal BCG)a n = 38 p-valueb
Infant characteristics
Days between PBMC collection and BCG vaccinationa,c,d 14 (83, 1) 60 (29, 90) –
Days between PBMC collection and Hepatitis B vaccination #1c,d 48 (9, 78) 63 (50, 75) p = 0.14
Days between PBMC collection and DPT vaccination #1c,d,f 14 (8, 35) 20 (13, 26) p = 0.8
Days between PBMC collection and OPV vaccination #1c,d 14 (8, 35) 20 (12, 26) p = 0.9
Age at time of PBMC collection (months)c,d,e 2.2 (2.0, 2.8) 2.6 (2.3, 2.8) p = 0.3
Gender (male:female) 10:3 23:15 p = 0.3
Manner of delivery (vaginal delivery:C-section) 12:1 33:5 p = 1.0
Breastfed infants (%)g 69% 87% p = 0.2
WHO weight-for-age z scored,h 0.28 (1.66, 1.09) 0.50 (2.01, 1.13) p = 0.6
WHO length-for-age z scored,h 0.38 (1.89, 0.72) 0.64 (3.18, 0.62) p = 0.5
WHO BMI-for-age z scored,h,i 0.00 (1.37, 1.68) 0.13 (1.20, 2.10) p = 1.0
WHO weight-for-length z scored,h 0.18 (1.62, 1.91) 0.42 (1.15, 2.83) p = 0.6
Mother characteristics
Maternal age at delivery (yrs)d 24.4 (21.4, 35.9) 21.8 (20.1, 26.1) p = 0.11
Gravidad 2 (1, 3) 2 (1, 3) p = 0.7
Paragravidad 2 (1, 3) 1 (1, 2) p = 0.6
Highest level of education attained Primary school-4 Primary school-8 p = 0.5
High school-6 High school-25
College/University-3 College/University-5
Number of persons in householdd 5 (4, 6) 6 (5, 7) p = 0.2
a BCG = Bacille Calmette Guérin vaccine.
b Comparisons between continuous variables were performed using the non-parametric Mann–Whitney U test; comparisons between categorical variables were per-
formed using the k2 test.
c PBMC = peripheral blood mononuclear cells.
d Values are median (95% conﬁdence interval).
e DPT = diphtheria, pertussis, tetanus toxoid vaccine.
f OPV = oral poliovirus vaccine.
g Breastfed = exclusive or supplemental breastfeeding.
h WHO =World Health Organization.
i BMI = body mass index.
Fig. 1. IFN-c ELISPOT assays to tetanus toxoid and polioviruses 1–3. The frequencies of IFN-c spot-forming cells (SFC)/106 peripheral blood mononuclear cells (PBMC) from 2–
3 months old infants to (a) tetanus toxoid and (b) inactivated poliovirus vaccine antigens are shown. Data points are the number of antigen-stimulated IFN-c SFC – media
control IFN-c SFC. Negative values mean the number of antigen stimulated IFN-c SFC was suppressed compared to media control. Bars are median values.
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In a case-control study, we found that BCG vaccination at birth
was associated with increased IFN-c SFC to tetanus toxoid
2–3 months later. There was also an increased trend in the fre-
quency of IFN-c SFC to polioviruses. The frequency of IFN-c+/
TNF-a+ CD45RO+CD4+ T-cells upon stimulation with PMA/Iono-
mycin was higher in 2–3 months old infants who received BCG
vaccination at birth compared to those who did not. The circulating
frequency of FoxP3+CD45RO+ regulatory CD4+ T-cells also trended
lower in these infants.
The tetanus toxoid and poliovirus vaccines induce predomi-
nantly Th1 cells during infancy [8–10], whereas neonatal hepatitisB vaccination is less reliant on Th1 induction [11,12]. Our IFN-c
ELISPOT results were consistent with these observations. The fre-
quencies of IFN-c SFC reﬂect a balance between Th1 and Th2 re-
sponses, which is why in some infants’ vaccine-stimulated
responses were lower than media-stimulated responses. Neonatal
BCG vaccination was associated with an increase in heterologous
Th1 responses 2–3 months later to the infant tetanus toxoid and
poliovirus vaccines. PHA induces IFN-c production in both anti-
gen-experienced (CD45RO+) and antigen-inexperienced
(CD45RO) CD4+ T-cells. The vast majority of infant CD4+ T-cells
were antigen-inexperienced (CD45RO), and there was no differ-
ence in the frequencies of IFN-c+ CD45ROCD4+ T-cells upon
PMA/Ionomycin stimulation between infants who received BCG
Fig. 2. IFN-c ELISPOT assays to hepatitis B surface antigen (sAg) and phytohemagglutinin (PHA). The frequencies of IFN-c spot-forming cells (SFC)/106 peripheral blood
mononuclear cells (PBMC) from 2–3 months old infants to (a) hepatitis B sAg and (b) PHA are shown. Data points are the number of antigen-stimulated IFN-c SFC – media
control IFN-c SFC. Negative values mean the number of antigen stimulated IFN-c SFC was suppressed compared to media control. Bars are median values.
Fig. 3. Intracellular cytokine staining for IFN-c+/TNF-a+ CD4+ T-cells in the PBMC from 2–3 months old infants. The frequencies of phorbol myristate acetate (PMA)/
Ionomycin stimulated – media control IFN-c and TNF-a producing (a) CD45RO+CD4+ T-lymphocytes or (b) CD45ROCD4+ T-lymphocytes are shown. Values are expressed as
the % of either CD45RO+ or CD45RO CD3+ CD4+ T-lymphocytes. Bars are median values.
Fig. 4. Ex vivo intracellular cytokine staining for forkhead box P3 (FoxP3)+ regulatory CD4+ T-cells in the PBMC from 2–3 months old infants. The circulating frequencies of
FoxP3+ (a) CD45RO+ CD4+ T-lymphocytes or (b) CD45ROCD4+ T-lymphocytes are shown. Values are expressed as the % of either CD45RO+ or CD45RO CD3+ CD4+
T-lymphocytes. Bars are median values.
4 D.H. Libraty et al. / Trials in Vaccinology 3 (2014) 1–5vaccination at birth and those who did not. As such, there was also
no difference in the frequencies of PHA-stimulated IFN-c SFC by
ELISPOT.
In one report, BCG vaccination increased in vitro PBMC IFN-c re-
lease to unrelated pathogens (Staphylococcus aureus and Candidaalbicans) for up to 3 months [13]. We postulate that BCG vaccina-
tion at birth primes neonatal dendritic cells to produce interleukin
(IL)-12 p70 upon encountering intracellular pathogens or toxins.
This Th1 polarizing effect of innate immunity lasts for several
months. The ability of innate immune cells to acquire some
D.H. Libraty et al. / Trials in Vaccinology 3 (2014) 1–5 5memory and have cross-reactive immune effects has been termed
‘‘trained’’ immunity [14].
The observation that the circulating frequency of FoxP3+
CD45RO+ CD4+ T-cells trended lower among 2–3 months old
infants who received BCG vaccination at birth is novel, but we
are unable to distinguish whether this might be a cause or effect
of Th1 polarization. One report demonstrated no signiﬁcant
difference in the ex vivo frequencies of FoxP3+CD4+ T-cells cells
4½ months after neonatal BCG vaccination [15]. Other limitations
of this study are those of case-control studies in general. A
prospective randomized study of neonatal BCG vaccination and
its Th1 immune effects in 2–3 months old infants is planned. The
fetal and early neonatal immune system is heavily Th2 biased
[16,17]. This bias is felt to contribute to many suboptimal vaccine
responses in neonates. The heterologous immune effects of BCG
vaccination at birth provide important clues on how to improve
neonatal and infant vaccine strategies.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.trivac.2013.11.
004.
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